Neurometabolic therapy is used ...

Neurometabolic therapy is used with symptomatic goal to reduce the severity of cognitive and other neurological disorders. In addition, according to some sources, metabolic therapy has the ability to modify the course of the disease. Class of drugs, specially synthesized for use as nootropic drugs are GABA-ergic preparations: piracetam and its modifications. Effectiveness of therapy depends largely on the dosage regimen. More appropriate to intravenous administration of relatively high doses [7]. As neurometabolic therapy is well established peptidergichesky drug cerebrolysin. Cerebrolysin contains free amino acids and polypeptides, which as shown by experimental observations, have neurotrophic effects [2,6]. It is shown that cerebrolysin with intravenous doses of 1530 ml has a beneficial effect, mainly on cognitive function, helping to improve concentration, mnemonic functions, and intellectual processes [1,14,20,35,39]. As nootropics atsetilholinergicheskie used drugs, given the role atsetilholinergicheskoy mediation in the process of attention and memory. Currently, it is proved that acetylcholinesterase inhibitors such as rivastigmine and amiridin, improve cognitive function in dementia of Alzheimer's type. When DOE and vascular dementia the drugs prescribed for appropriate mixed character of dementia with concomitant degenerative process. It should be noted that acetylcholinesterase inhibitors may increase the severity of depression. Therefore, a combination of cognitive and emotional disorders, treatment should begin with a correction of the symptoms of depression. In order to enhance atsetilholinergicheskoy mediation as Alzheimer's disease and in vascular dementia is also used by the predecessor of acetylcholine gliatilin [7, 36]. In the pharmacotherapy of depression associated with cerebral vascular insufficiency, is preferable to the appointment of agents with minimal cholinolytic effect, since the latter may aggravate the severity of cognitive impairment. The most appropriate use of selective serotonin reuptake inhibitors such as fluoxetine [36]. Easy antidepressant effect in vascular mogovoy failure is also described in Tanakan, which can be used for symptomatic non-severe depression associated with ED [31]. Conclusion Thus, cognitive and emotional disturbances are a legitimate part of clinical dyscirculatory encephalopathy. The basis of mental disorders in the ED is the defeat of the deep divisions of the cerebral hemispheres (basal ganglia and the deep divisions of white matter) associated with both chronic hypoperfusion, as well as with recurrent acute disorders of cerebral circulation. The defeat of the deep cerebral departments leads to uncoupling of connections frontal regions and subcortical structures, which leads to secondary dysfunction of the frontal lobes of the brain, which are the manifestation of cognitive dysfunction of subcortical-frontal nature and symptoms of depression.